SoftBank Vision Fund 2 and Cormorant Asset Management led a $210m Series B funding round in Umoja Biopharma.

SoftBank Vision Fund 2, a venture capital fund, and Cormorant Asset Management, a hedge fund sponsor, led a $210m Series B funding round in Umoja Biopharma, a preclinical-stage company, that develops an entirely new approach to the therapy. Additional investors included RTW Investments, Temasek, Presight Capital, Caas Capital, and an investment fund associated with SVB Leerink. Company's existing investors include: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective, and Alexandria Venture Investments. "Umoja has made tremendous strides in the past year, including advancing our preclinical programs, expanding manufacturing capabilities, and bringing on key hires to prepare for our next phase of development and growth," Andrew Scharenberg, Umoja Biopharma Co-Founder and CEO.